<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: In a few previous studies, <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk factors (RFs) have been shown to predict <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Our objective was to determine whether the presence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> RFs predict the eventual development of <z:mp ids='MP_0002055'>diabetes</z:mp> after controlling for known RFs, such as directly measured <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We studied 872 participants with <z:mpath ids='MPATH_458'>normal</z:mpath> or <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) who were enrolled at baseline in the <z:hpo ids='HP_0000855'>Insulin Resistance</z:hpo> <z:hpo ids='HP_0002621'>Atherosclerosis</z:hpo> Study (IRAS) </plain></SENT>
<SENT sid="3" pm="."><plain>Of these, 143 (16%) developed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in 5 years </plain></SENT>
<SENT sid="4" pm="."><plain>Using these participants, a series of logistic regression models were fit to address the question </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Significant RFs for developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> included high plasminogen activator inhibitor-1, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, high <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, low levels of <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, and IGT </plain></SENT>
<SENT sid="6" pm="."><plain>The 5-year cumulative incidence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by the number of RFs (0-5) was as follows: no RFs, 11 of 230 = 5%; one RF, 31 of 278 = 11%; two RFs, 36 of 202 = 18%; three RFs, 41 of 110 = 37%; four RFs, 19 of 42 = 45%; and five RFs, 5 of 10 = 50% (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>The odds ratio (OR) for conversion to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> for each additional RF was 2.1 (95% CI 1.78-2.46) after adjusting for age, sex, ethnicity, and center </plain></SENT>
<SENT sid="8" pm="."><plain>After further adjustment for <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, determined by the frequently sampled intravenous <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test and waist circumference, each additional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> RF increased the risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> significantly (OR 1.81, 95% CI 1.49-2.20) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Individuals with multiple <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> RFs are at increased risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, which is only partially mediated by <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> or central <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>This information should be useful for identifying high-risk patients for developing <z:mp ids='MP_0002055'>diabetes</z:mp> through RF assessments </plain></SENT>
</text></document>